Zhou H, Davis HM. Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. Drug Discov Today 2009;14:891–8.CrossrefGoogle Scholar

Mahmood I, Green MD. Drug interaction studies of therapeutic proteins or monoclonal antibodies. J Clin Pharmacol 2007;47:1540–54.CrossrefPubMedGoogle Scholar

Lee JI, Zhang L, Men AY, Kenna LA, Huang SM. CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin Pharmacokinet 2010;49:295–310.CrossrefPubMedGoogle Scholar

Huang SM, Zhao H, Lee JI, Reynolds K, Zhang L, Temple R, et al. Therapeutic protein-drug interactions and implications for drug development. Clin Pharmacol Ther 2010;87:497–503.PubMedCrossrefGoogle Scholar

Zidek Z, Anzenbacher P, Kmonickova E. Current status and challenges of cytokine pharmacology. Br J Pharmacol 2009;157:342–61.Google Scholar

Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 1997;29:1129–88.Google Scholar

Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 2006;46:123–49.PubMedCrossrefGoogle Scholar

Petrovic V, Teng S, Piquette-Miller M. Regulation of drug transporters during infection and inflammation. Mol Interv 2007;7:99–111.PubMedCrossrefGoogle Scholar

Kashuba AD, Hawke RL, Tonkin J, LeCluyse EL. Direct exposure to interleukins (IL)-2, −10, and −12 does not significantly suppress CYP3A activity in human hepatocytes. Clin Pharmacol Ther 2000;89:100.Google Scholar

Muntane-Relat J, Ourlin JC, Domergue J, Maurel P. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 1995;22:1143–53.CrossrefGoogle Scholar

Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993;44:707–15.Google Scholar

Abdel-Razzak Z, Corcos L, Fautrel A, Campion JP, Guillouzo A. Transforming growth factor-β1 down-regulates basal and polycyclic aromatic hydrocarbon-induced cytochromes P-450 1A1 and 1A2 in adult human hepatocytes in primary culture. Mol Pharmacol 1994;46:1100–10.Google Scholar

Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 2007;35:1687–93.Google Scholar

Assenat E, Gerbal-Chaloin S, Larrey D, Saric J, Fabre JM, Maurel P, et al. Interleukin 1β inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. Hepatology 2004;40:951–60.CrossrefGoogle Scholar

Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD. Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos 2004;32:359–63.Google Scholar

Kleine M, Schrem H, Borlak J, Klempnauer J. Clinical versatility of porcine hepatocytes in the light of interspecies differences in cytochrome P450 regulation and expression. Xenotransplantation 2008;15:208–17.Google Scholar

Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, Daujat M, Fabre JM, Maurel P, et al. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 2000;274:707–13.Google Scholar

Yang J, Hao C, Yang D, Shi D, Song X, Luan X, et al. Pregnane X receptor is required for interleukin-6-mediated down-regulation of cytochrome P450 3A4 in human hepatocytes. Toxicol Lett 2010;197:219–26.Google Scholar

Guillen MI, Donato MT, Jover R, Castell JV, Fabra R, Trullenque R, et al. Oncostatin M down-regulates basal and induced cytochromes P450 in human hepatocytes. J Pharmacol Exp Ther 1998;285:127–34.Google Scholar

Kalsotra A, Anakk S, Brommer CL, Kikuta Y, Morgan ET, Strobel HW. Catalytic characterization and cytokine mediated regulation of cytochrome P450 4Fs in rat hepatocytes. Arch Biochem Biophys 2007;461:104–12.Google Scholar

Umannova L, Machala M, Topinka J, Novakova Z, Milcova A, Kozubik A, et al. Tumor necrosis factor-α potentiates genotoxic effects of benzo[a]pyrene in rat liver epithelial cells through upregulation of cytochrome P450 1B1 expression. Mutat Res 2008;640:162–9.Google Scholar

Fukuda Y, Sassa S. Suppression of cytochrome P450IA1 by interleukin-6 in human HepG2 hepatoma cells. Biochem Pharmacol 1994;47:1187–95.Google Scholar

Bertilsson PM, Olsson P, Magnusson KE. Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells. J Pharm Sci 2001;90:638–46.Google Scholar

Nicholson TE, Renton KW. The role of cytokines in the depression of CYP1A activity using cultured astrocytes as an in vitro model of inflammation in the central nervous system. Drug Metab Dispos 2002;30:42–6.CrossrefGoogle Scholar

Stanley LA, Carmichael J, Wolf CR. Cytochrome P-450 induction in human lung tumor-derived cell lines. Characterisation and effects of inflammatory mediators. Eur J Biochem 1992;208:521–9.Google Scholar

Roberts RA, Ganey PE, Ju C, Kamendulis LM, Rusyn I, Klaunig JE. Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci 2007;96:2–15.PubMedGoogle Scholar

Peterson TC, Renton KW. Kupffer cell factor mediated depression of hepatic parenchymal cell cytochrome P-450. Biochem Pharmacol 1986;35:1491–7.Google Scholar

Milosevic N, Schawalder H, Maier P. Kupffer cell-mediated differential down-regulation of cytochrome P450 metabolism in rat hepatocytes. Eur J Pharmacol 1999;368:75–87.Google Scholar

Jover R, Bort R, Gomez-Lechon MJ, Castell JV. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J 2002;16:1799–801.Google Scholar

Tinel M, Elkahwaji J, Robin MA, Fardel N, Descatoire V, Haouzi D, et al. Interleukin-2 overexpresses c-myc and down-regulates cytochrome P-450 in rat hepatocytes. J Pharmacol Exp Ther 1999;289:649–55.Google Scholar

Peng HM, Coon MJ. Promoter function and the role of cytokines in the transcriptional regulation of rabbit CYP2E1 and CYP2E2. Arch Biochem Biophys 2000;382:129–37.Google Scholar

Iber H, Chen Q, Cheng PY, Morgan ET. Suppression of CYP2C11 gene transcription by interleukin-1 mediated by NF-κB binding at the transcription start site. Arch Biochem Biophys 2000;377:187–94.Google Scholar

Cheng PY, Wang M, Morgan ET. Rapid transcriptional suppression of rat cytochrome P450 genes by endotoxin treatment and its inhibition by curcumin. J Pharmacol Exp Ther 2003;307:1205–12.Google Scholar

Morel Y, Barouki R. Down-regulation of cytochrome P450 1A1 gene promoter by oxidative stress. Critical contribution of nuclear factor 1. J Biol Chem 1998;273:26969–76.Google Scholar

Wang B, Cai SR, Gao C, Sladek FM, Ponder KP. Lipopolysaccharide results in a marked decrease in hepatocyte nuclear factor 4α in rat liver. Hepatology 2001;34:979–89.Google Scholar

Hakkola J, Hu Y, Ingelman-Sundberg M. Mechanisms of down-regulation of CYP2E1 expression by inflammatory cytokines in rat hepatoma cells. J Pharmacol Exp Ther 2003;304:1048–54.Google Scholar

Xu DX, Wang JP, Sun MF, Chen YH, Wei W. Lipopolysaccharide downregulates the expressions of intestinal pregnane X receptor and cytochrome P450 3a11. Eur J Pharmacol 2006;536:162–70.Google Scholar

Beigneux AP, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. Biochem Biophys Res Commun 2002;293:145–9.Google Scholar

Fang C, Yoon S, Tindberg N, Jarvelainen HA, Lindros KO, Ingelman-Sundberg M. Hepatic expression of multiple acute phase proteins and down-regulation of nuclear receptors after acute endotoxin exposure. Biochem Pharmacol 2004;67:1389–97.CrossrefGoogle Scholar

Wu R, Cui X, Dong W, Zhou M, Simms HH, Wang P. Suppression of hepatocyte CYP1A2 expression by Kupffer cells via AhR pathway: the central role of proinflammatory cytokines. Int J Mol Med 2006;18:339–46.Google Scholar

Xu DX, Wei W, Sun MF, Wu CY, Wang JP, Wei LZ, et al. Kupffer cells and reactive oxygen species partially mediate lipopolysaccharide-induced downregulation of nuclear receptor pregnane x receptor and its target gene CYP3a in mouse liver. Free Radic Biol Med 2004;37:10–22.Google Scholar

Teng S, Piquette-Miller M. The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. J Pharmacol Exp Ther 2005;312:841–8.Google Scholar

Sachdeva K, Yan B, Chichester CO. Lipopolysaccharide and cecal ligation/puncture differentially affect the subcellular distribution of the pregnane X receptor but consistently cause suppression of its target genes CYP3A. Shock 2003;19:469–74.CrossrefGoogle Scholar

Richardson TA, Morgan ET. Hepatic cytochrome P450 gene regulation during endotoxin-induced inflammation in nuclear receptor knockout mice. J Pharmacol Exp Ther 2005;314:703–9.Google Scholar

Van Ess PJ, Mattson MP, Blouin RA. Enhanced induction of cytochrome P450 enzymes and CAR binding in TNF (p55^-/-/p75^-/-) double receptor knockout mice following phenobarbital treatment. J Pharmacol Exp Ther 2002;300:824–30.Google Scholar

Carlson TJ, Billings RE. Role of nitric oxide in the cytokine-mediated regulation of cytochrome P-450. Mol Pharmacol 1996;49:796–801.Google Scholar

Liaudet L, Soriano FG, Szabo C. Biology of nitric oxide signaling. Crit Care Med 2000;28:N37–52.CrossrefGoogle Scholar

Donato MT, Guillen MI, Jover R, Castell JV, Gomez-Lechon MJ. Nitric oxide-mediated inhibition of cytochrome P450 by interferon-γ in human hepatocytes. J Pharmacol Exp Ther 1997;281:484–90.Google Scholar

Aitken AE, Lee CM, Morgan ET. Roles of nitric oxide in inflammatory downregulation of human cytochromes P450. Free Radic Biol Med 2008;44:1161–8.Google Scholar

Lee CM, Kim BY, Li L, Morgan ET. Nitric oxide-dependent proteasomal degradation of cytochrome P450 2B proteins. J Biol Chem 2008;283:889–98.Google Scholar

Lee CM, Pohl J, Morgan ET. Dual mechanisms of CYP3A protein regulation by proinflammatory cytokine stimulation in primary hepatocyte cultures. Drug Metab Dispos 2009;37:865–72.CrossrefGoogle Scholar

Sewer MB, Morgan ET. Nitric oxide-independent suppression of P450 2C11 expression by interleukin-1β and endotoxin in primary rat hepatocytes. Biochem Pharmacol 1997;54:729–37.Google Scholar

Geller DA, Freeswick PD, Nguyen D, Nussler AK, Di Silvio M, Shapiro RA, et al. Differential induction of nitric oxide synthase in hepatocytes during endotoxemia and the acute-phase response. Arch Surg 1994;129:165–71.Google Scholar

Nussler AK, Di Silvio M, Billiar TR, Hoffman RA, Geller DA, Selby R, et al. Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J Exp Med 1992;176:261–4.Google Scholar

Geller DA, Nussler AK, Di Silvio M, Lowenstein CJ, Shapiro RA, Wang SC, et al. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci USA 1993;90:522–6.CrossrefGoogle Scholar

Delaporte E, Renton KW. Cytochrome P4501A1 and cytochrome P4501A2 are downregulated at both transcriptional and post-transcriptional levels by conditions resulting in interferon-α/β induction. Life Sci 1997;60:787–96.Google Scholar

Cherrington NJ, Slitt AL, Li N, Klaassen CD. Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab Dispos 2004;32:734–41.CrossrefGoogle Scholar

Elferink MG, Olinga P, Draaisma AL, Merema MT, Faber KN, Slooff MJ, et al. LPS-induced downregulation of MRP2 and BSEP in human liver is due to a posttranscriptional process. Am J Physiol Gastrointest Liver Physiol 2004;287:G1008–16.Google Scholar

Englund G, Jacobson A, Rorsman F, Artursson P, Kindmark A, Ronnblom A. Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1). Inflamm Bowel Dis 2007;13:291–7.CrossrefGoogle Scholar

Siewert E, Dietrich CG, Lammert F, Heinrich PC, Matern S, Gartung C, et al. Interleukin-6 regulates hepatic transporters during acute-phase response. Biochem Biophys Res Commun 2004;322:232–8.Google Scholar

Hartmann G, Cheung AK, Piquette-Miller M. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther 2002;303:273–81.Google Scholar

Ho EA, Piquette-Miller M. Regulation of multidrug resistance by pro-inflammatory cytokines. Curr Cancer Drug Targets 2006;6:295–311.CrossrefGoogle Scholar

Vee ML, Lecureur V, Stieger B, Fardel O. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-α or interleukin-6. Drug Metab Dispos 2009;37:685–93.CrossrefGoogle Scholar

Le Vee M, Gripon P, Stieger B, Fardel O. Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1β. Drug Metab Dispos 2008;36:217–22.Google Scholar

Nakai K, Tanaka H, Hanada K, Ogata H, Suzuki F, Kumada H, et al. Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na⁺-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients. Drug Metab Dispos 2008;36:1786–93.Google Scholar

Bohan A, Chen WS, Denson LA, Held MA, Boyer JL. Tumor necrosis factor α-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis. J Biol Chem 2003;278:36688–98.Google Scholar

Lee G, Piquette-Miller M. Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells. Can J Physiol Pharmacol 2001;79:876–84.Google Scholar

Diao L, Li N, Brayman TG, Hotz KJ, Lai Y. Regulation of MRP2/ABCC2 and BSEP/ABCB11 expression in sandwich cultured human and rat hepatocytes exposed to inflammatory cytokines TNF-α, IL-6, and IL-1β. J Biol Chem 2010;285:31185–92.Google Scholar

Poller B, Drewe J, Krahenbuhl S, Huwyler J, Gutmann H. Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cell Mol Neurobiol 2010;30:63–70.CrossrefGoogle Scholar

Heemskerk S, Peters JG, Louisse J, Sagar S, Russel FG, Masereeuw R. Regulation of P-glycoprotein in renal proximal tubule epithelial cells by LPS and TNF-α. J Biomed Biotechnol 2010;2010:525180.Google Scholar

Strasser SI, Mashford ML, Desmond PV. Regulation of uridine diphosphate glucuronosyltransferase during the acute-phase response. J Gastroenterol Hepatol 1998;13:88–94.CrossrefGoogle Scholar

Monshouwer M, Witkamp RF, Nujmeijer SM, Van Amsterdam JG, Van Miert AS. Suppression of cytochrome P450- and UDP glucuronosyl transferase-dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes. Toxicol Appl Pharmacol 1996;137:237–44.Google Scholar

Levesque E, Beaulieu M, Guillemette C, Hum DW, Belanger A. Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line. Endocrinology 1998;139:2375–81.Google Scholar

Maheo K, Antras-Ferry J, Morel F, Langouet S, Guillouzo A. Modulation of glutathione S-transferase subunits A2, M1, and P1 expression by interleukin-1β in rat hepatocytes in primary culture. J Biol Chem 1997;272:16125–32.Google Scholar

Voss SH, Park Y, Kwon SO, Whalen R, Boyer TD. Role of interleukin 6 and corticosteroids in the regulation of expression of glutathione S-transferases in primary cultures of rat hepatocytes. Biochem J 1996;317(Pt 2):627–32.Google Scholar

Langouet S, Corcos L, Abdel-Razzak Z, Loyer P, Ketterer B, Guillouzo A. Up-regulation of glutathione S-transferases α by interleukin 4 in human hepatocytes in primary culture. Biochem Biophys Res Commun 1995;216:793–800.Google Scholar

Kim MS, Shigenaga J, Moser A, Grunfeld C, Feingold KR. Suppression of DHEA sulfotransferase (Sult2A1) during the acute-phase response. Am J Physiol Endocrinol Metab 2004;287:E731–8.Google Scholar

Machavaram KK, Almond LM, Rostami-Hodjegan A, Gardner I, Jamei M, Tay S, et al. A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6. Clin Pharmacol Ther 2013;94:260–8.Google Scholar